Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The aim of this study was to test whether survival for patients with high-grade non-Hodgkin's lymphoma (NHL) can be improved with a non-cross-resistant regimen as compared to a CHOP-based regimen. This is a multicentre study comprising 325 adult patients, median age 58 years, with high-grade non-Hodgkin's lymphoma: patients of any age and performance status were eligible provided they were able to receive the drugs in the regimens. Patients were randomised to either B-CHOP-M (bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisolone and methotrexate) or PEEC-M (methylprednisolone, vindesine, etoposide, chlorambucil and methotrexate) alternating with B-CHOP-M. At a median follow-up of 9 years, there was no significant difference in overall survival or disease-free survival between the two arms. Toxicities for the two regimens were equivalent. This study confirms that for relatively unselected patients with high-grade non-Hodgkin's lymphoma, an alternating multidrug regimen does not improve upon the results obtained with B-CHOP-M.

Original publication

DOI

10.1016/s0959-8049(97)00051-8

Type

Journal article

Journal

European journal of cancer (Oxford, England : 1990)

Publication Date

07/1997

Volume

33

Pages

1195 - 1201

Addresses

Department of Clinical Oncology, Western General Hospital, Edinburgh, U.K.

Keywords

Humans, Lymphoma, Non-Hodgkin, Chlorambucil, Cyclophosphamide, Vincristine, Vindesine, Methotrexate, Doxorubicin, Etoposide, Prednisolone, Methylprednisolone, Bleomycin, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Drug Administration Schedule, Survival Rate, Follow-Up Studies, Adult, Aged, Middle Aged